Bivalirudin
250mg
Bivalirudin is an antithrombotic medicine which prevent the formation of blood clots (thrombosis). It is indicated as an anticoagulant in adult patients undergoing percutaneous coronary intervention (PCI), including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI. It is also indicated for the treatment of adult patients with unstable angina/non-ST segment elevation myocardial infarction (UA/NSTEMI) planned for urgent or early intervention. It should be administered with acetylsalicylic acid and clopidogrel.
For more information, please refer to the Educational Materials below.
| Name & Details | Packaging | Strength | Form | Pack Size |
|---|---|---|---|---|
| Bivalirudin 250 mg powder for concentrate for solution for injection or infusion | Glass vial | 250mg | Powder for concentrate for solution for injection or infusion | 1 x 10ml vial |
Pack type: 1 x 10ml vial
PIP code: 1255926
Product licence number: PL 44853/0083
Product EAN Code: 5060467000390
Product Classification: POM Hospital Only
Categories: Antithrombotic
Support Documentation
If you need further information on this product, please access the Educational Materials below and the current Summary of Product Characteristics (SmPC) and Patient information leaflet (PIL) on the MHRA website using the aforementioned product license number.
Dosing and administration instructions for medically managed ACS patients with urgent or early intervention download Bivalirudin EM 1 Urgent Intervention [PDF]
Dosing and administration instructions for PCI and primary PCI download Bivalirudin EM 2 PCI [PDF]
MHRA website (click here to open external website in a new window)